Enlivex Therapeutics (Nasdaq: ENLV) Information

Enlivex (NASDAQ: ENLV) drives shareholder value through two parallel engines: Managing an active digital asset treasury anchored by the Rain prediction markets protocol ($RAIN) and developing Allocetra™ for immune rebalancing. Pillar 1: Active Digital Asset Treasury We are the first public company to adopt a treasury strategy centered on the Rain protocol ($RAIN)—a decentralized platform for prediction markets. Unlike passive holding strategies, we actively manage these assets through staking and yield generation to grow our corporate capital. Pillar 2: Clinical Development We are a clinical-stage immunotherapy company developing Allocetra™, a cell-based therapy designed to rebalance the immune system rather than suppress it. Our primary clinical focus is addressing the significant unmet need in knee osteoarthritis, aiming to provide relief for millions of patients worldwide. Highlights: ● Ticker: NASDAQ: ENLV ● Clinical Core: Late-stage development of Allocetra™ for osteoarthritis and acute conditions. ● Strategic Treasury: Anchored by the $RAIN token, aligning our growth with the expanding prediction market sector. ● Innovation: A dual-engine approach combining scientific rigor with forward-thinking capital management.